Sara Martinez Martinez

Sara Martinez Martinez

Auto-generated profile, based on publicly available information

Sara Martinez Martinez

CIMUS, University of Santiago de Compostela, Instituto de Investigación Sanitaria, Santiago de Compostela, Spain

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2022 in Nature Metabolism
Verified
Journal Article
Open access
PDF file
VPVerónica Pena-Leon
Verónica Pena-Leon
CFCintia Folgueira
Cintia Folgueira
SBSilvia Barja-Fernández
Silvia Barja-Fernández
RPRaquel Pérez-Lois
Raquel Pérez-Lois
Natalia da Silva LimaNatalia da Silva Lima
Natalia da Silva Lima
LSLuisa M Seoane
Luisa M Seoane
Early-life determinants are thought to be a major factor in the rapid increase of obesity. However, while maternal nutrition has been extensively studied, the effects of breastfeeding by the infant on the reprogramming of energy balance in childhood and throughout adulthood remain largely unknown. Here we show that delayed weaning in rat pups protects them against diet-induced obesity in adulthood, through enhanced brown adipose tissue thermogenesis and energy expenditure. In-depth metabolic phenotyping in this rat model as well as in transgenic mice reveals that the effects of prolonged suckling are mediated by increased hepatic fibroblast growth factor 21 (FGF21) production and tanycyte-controlled access to the hypothalamus in adulthood. Specifically, FGF21 activates GABA-containing neurons expressing dopamine receptor 2 in the lateral hypothalamic area and zona incerta. Prolonged breastfeeding thus constitutes a protective mechanism against obesity by affecting long-lasting physiological changes in liver-to-hypothalamus communication and hypothalamic metabolic regulation.

22 April 2025 in Nature Metabolism
Verified
Journal Article
Open access
PDF file
MTMíriam Toledo
Míriam Toledo
SMSara Martínez-Martínez
Sara Martínez-Martínez
MHMatthias Van Hul
Matthias Van Hul
BLBerta Laudo
Berta Laudo
EEElena Eyre
Elena Eyre
MCMarc Claret
Marc Claret
In recent years, the gut microbiota and derived metabolites have emerged as relevant players in modulating several brain functions, including energy balance control1,2,3. This form of distant communication mirrors that of metabolic hormones (for example, leptin, ghrelin), which convey information about the organism’s energy status by exerting effects on diverse brain regions, including the master homeostatic centre, the hypothalamus4. However, whether the hypothalamus is also able to influence gut microbiota composition remains enigmatic. Here we present a study designed to unravel this challenging question. To this aim, we used chemogenetics5 (to selectively activate or inhibit hypothalamic pro-opiomelanocortin or agouti-related peptide neurons) or centrally administered leptin or ghrelin to male mice. Subsequently, we conducted microbiota composition analysis throughout the gut using 16S rRNA gene sequencing. Our results showed that these brain interventions significantly changed the gut microbiota in an anatomical and short-term (2–4 h) fashion. Transcriptomic analysis indicated that these changes were associated with the reconfiguration of neuronal and synaptic pathways in the duodenum concomitant with increased sympathetic tone. Interestingly, diet-induced obesity attenuated the brain-mediated changes triggered by leptin in gut microbiota communities and sympathetic activation. Our findings reveal a previously unanticipated brain–gut axis that acutely attunes microbiota composition on fast timescales, with potential implications for meal-to-meal adjustments and systemic energy balance control.

29 April 2026 in Nature
Verified
Journal Article
Open access
PDF file
DLDaniela Liskiewicz
Daniela Liskiewicz
ANAaron Novikoff
Aaron Novikoff
AKAhmed Khalil
Ahmed Khalil
SASeun Akindehin
Seun Akindehin
JCJonathan E. Campbell
Jonathan E. Campbell
Timo D. MüllerTimo D. Müller
Timo D. Müller
There are increasing numbers of effective drugs to improve obesity-linked metabolic dysfunction; GLP-1R–GIPR co-agonism is effective in the management of obesity and type 2 diabetes 1,2 , and lanifibranor—a nuclear-acting small-molecule triple agonist of PPARα, PPARγ and PPARδ—is in clinical phase 3 trials for the treatment of metabolic dysfunction-associated steatohepatitis 3 . Here, seeking to further improve the metabolic efficacy of GLP-1R–GIPR co-agonism, we report the development of a unimolecular quintuple agonist that combines the body weight-reducing and blood glucose-lowering effects of GLP-1R–GIPR co-agonism with the insulin-sensitizing and anti-inflammatory effects of lanifibranor via its targeted delivery into GLP-1R- and GIPR-expressing cells. In vitro, GLP-1–GIP–lanifibranor is indistinguishable from GLP-1–GIP in relation to incretin receptor signalling and shows equal stimulation of insulin secretion in isolated mouse islets. In vivo, however, GLP-1–GIP–lanifibranor outperforms GLP-1R–GIPR co-agonism and semaglutide, further decreasing body weight, food intake and hyperglycaemia in obese and insulin-resistant mice through synergistic incretin and PPAR action. The metabolic action of GLP-1–GIP–lanifibranor is blunted in mice with genetic or pharmacological inhibition of GLP-1R, GIPR or PPARδ and is absent in DIO double incretin receptor-knockout mice, collectively suggesting that GLP-1–GIP–lanifibranor has substantial therapeutic value in the treatment of obesity and diabetes.

18 May 2026 in Nature
Verified
Journal Article
Open access
PDF file
DLDaniela Liskiewicz
Daniela Liskiewicz
ANAaron Novikoff
Aaron Novikoff
AKAhmed Khalil
Ahmed Khalil
SASeun Akindehin
Seun Akindehin
JCJonathan E. Campbell
Jonathan E. Campbell
Timo D. MüllerTimo D. Müller
Timo D. Müller